Low-dose interleukin-2 in patients with stable ischaemic heart disease and acute coronary syndromes (LILACS): protocol and study rationale for a randomised, double-blind, placebo-controlled, phase I/II clinical trial

INTRODUCTION: Inflammation and dysregulated immune responses play a crucial role in atherosclerosis, underlying ischaemic heart disease (IHD) and acute coronary syndromes (ACSs). Immune responses are also major determinants of the postischaemic injury in myocardial infarction. Regulatory T cells (CD...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Tian Xiao, Kostapanos, Michalis, Griffiths, Charmaine, Arbon, Emma L, Hubsch, Annette, Kaloyirou, Fotini, Helmy, Joanna, Hoole, Stephen P, Rudd, James H F, Wood, Graham, Burling, Keith, Bond, Simon, Cheriyan, Joseph, Mallat, Ziad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2018
Materias:
Cardiovascular Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6144322/
https://www.ncbi.nlm.nih.gov/pubmed/30224390
http://dx.doi.org/10.1136/bmjopen-2018-022452

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6144322/
https://www.ncbi.nlm.nih.gov/pubmed/30224390
http://dx.doi.org/10.1136/bmjopen-2018-022452

Ejemplares similares